Reply to the Comments by Doherty et al
- PMID: 33091915
- DOI: 10.1159/000511830
Reply to the Comments by Doherty et al
Comment on
-
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.Psychother Psychosom. 2021;90(1):41-48. doi: 10.1159/000510703. Epub 2020 Aug 27. Psychother Psychosom. 2021. PMID: 32854103
-
Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis.Psychother Psychosom. 2021;90(2):138-139. doi: 10.1159/000512311. Epub 2020 Oct 27. Psychother Psychosom. 2021. PMID: 33108791 Free PMC article. No abstract available.
Publication types
LinkOut - more resources
Full Text Sources